Sarepta stock catapulted Thursday after the company announced a restructuring that includes 500 layoffs in the wake of two patient deaths.

At the FDA's request, delandistrogene moxeparvovec (Elevidys), the only approved gene therapy for Duchenne muscular dystrophy ...

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Sarepta Therapeutics is facing a challenging period after the deaths of two patients who received its Columbus-invented gene ...

Investing.com -- Precision BioSciences (NASDAQ: DTIL) has received FDA Orphan Drug Designations for its nuclease treatments targeting Duchenne muscular dystrophy.

Sarepta's shares jump after unveiling a major restructuring plan to cut costs. The company shifts focus to siRNA and reprioritizes its pipeline.

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Disabled Oasis fan Mark Chapman has slammed gig organisers after witnessing dozens of fans on the accessible platform at Heaton Park stand and abandon mobility aids when the band began playing. Mark, ...

Sarepta Therapeutics Inc. is cutting more than one-third of its workforce and will add a black box warning label to its gene therapy for a fatal muscle disorder after two patient deaths raised doubts ...

The first patient has been dosed in a clinical trial testing Sardocor's one-time gene therapy for cardiomyopathy associated ...

The company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.

Norwegian documentary, The Remarkable Life of Ibelin, directed by Benjamin Ree, chronicles the life of Mats Steen, who had ...